Chelation of Mitochondrial Iron as an Antiparasitic Strategy

Area of Science:

• Biochemistry
• Parasitology
• Drug Discovery

Background:

• Iron is vital for host-pathogen interactions, with innate immunity limiting pathogen growth by sequestering iron.
• Unicellular parasites possess sophisticated mechanisms to acquire iron, counteracting host defenses.
• Iron chelators, like deferoxamine (DFO), are potential therapeutic agents, particularly when targeted to mitochondria where iron is heavily utilized.

Purpose of the Study:

• To develop and evaluate mitochondrially targeted deferoxamine (mitoDFO) as a therapeutic candidate against unicellular parasites.
• To investigate the mode of action of mitoDFO in parasitic infections.
• To assess the potential of mitoDFO against a broad range of microbe-associated diseases.

Main Methods:

• Mitochondrial targeting of deferoxamine (DFO) to create mitoDFO.
• In vitro efficacy testing of mitoDFO against various unicellular parasites, including *Leishmania* and *Trypanosoma brucei* 427.
• Investigation of mitoDFO's effects on iron homeostasis and mitochondrial membrane properties.
• Evaluation of mitoDFO against virulence factors of pathogenic yeasts.

Main Results:

• MitoDFO demonstrated promising in vitro efficacy against a range of unicellular parasites.
• Intracellular *Leishmania* infections were cleared by mitoDFO.
• Experimentation with *Trypanosoma brucei* 427 revealed that mitoDFO disrupts iron homeostasis and alters the physiochemical properties of the inner mitochondrial membrane, leading to loss of function.
• MitoDFO showed potential against pathogenic yeasts.

Conclusions:

• MitoDFO is a potent candidate for therapeutic intervention against unicellular parasites.
• Targeting iron chelators to mitochondria represents an effective strategy for combating parasitic infections.
• MitoDFO holds promise for treating a wide spectrum of microbe-associated diseases.